Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30208243 | 1.00 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL31153540 | 0.90 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL165225 | 0.90 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL689369 | 0.87 | KDM4E (0.55) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL4933923 | 0.86 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL8200870 | 0.86 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL13343442 | 0.86 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL687822 | 0.85 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL689649 | 0.85 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDHSD17B10PDE3B | |
| SCHEMBL31574222 | 0.85 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4050005-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-115806550-A | Bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-109641886-B | Bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-4050005-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-3380469-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | CONVERGENE, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC | 2020-07-16 | — | — | US | disclosed |
| US-20180305344-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY | 2018-10-25 | — | — | US | disclosed |
| EP-3380469-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-3126350-B1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2018-07-04 | — | — | EP | disclosed |
| US-9908868-B2 | Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2018-03-06 | — | — | US | disclosed |
| WO-2017091661-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | STROVEL JEFFREY WILLIAM (US) | 2017-06-01 | — | — | WO | disclosed |
| EP-3126350-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022182-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150565-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2015-10-08 | — | — | WO | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| WO-2008063668-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022182-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GPR65, GPR88 | ALDH1A1 1596/4885SMN1; SMN2 4766/4885KDM4E 3000/4885 |
| US-20180305344-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRD3, BRDT | ALDH1A1 4523/4885SMN1; SMN2 3189/4885KDM4E 854/4885 |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | BRDT, BRD4, BRD3 | ALDH1A1 4433/4885SMN1; SMN2 3432/4885KDM4E 874/4885 |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ALDH1A1 1871/4885SMN1; SMN2 4520/4885KDM4E 1572/4885 |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | BRDT, BRD4, BRD3 | ALDH1A1 4433/4885SMN1; SMN2 3432/4885KDM4E 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.